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Abstract
Background: The function of BRCA1 in response to ionizing radiation, which directly generates DNA double strand breaks,
has been extensively characterized. However previous investigations have produced conflicting data on mutagens that
initially induce other classes of DNA adducts. Because of the fundamental and clinical importance of understanding BRCA1
function, we sought to rigorously evaluate the role of this tumor suppressor in response to diverse forms of genotoxic
stress.
Methodology/Principal Findings: We investigated BRCA1 stability and localization in various human cells treated with
model mutagens that trigger different DNA damage signaling pathways. We established that, unlike ionizing radiation,
either UVC or methylmethanesulfonate (MMS) (generating bulky DNA adducts or alkylated bases respectively) induces a
transient downregulation of BRCA1 protein which is neither prevented nor enhanced by inhibition of PIKKs. Moreover, we
found that the proteasome mediates early degradation of BRCA1, BARD1, BACH1, and Rad52 implying that critical
components of the homologous recombinaion machinery need to be functionally abrogated as part of the early response
to UV or MMS. Significantly, we found that inhibition of BRCA1/BARD1 downregulation is accompanied by the unscheduled
recruitment of both proteins to chromatin along with Rad51. Consistently, treatment of cells with MMS engendered
complete disassembly of Rad51 from pre-formed ionizing radiation-induced foci. Following the initial phase of BRCA1/
BARD1 downregulation, we found that the recovery of these proteins in foci coincides with the formation of RPA and Rad51
foci. This indicates that homologous recombination is reactivated at later stage of the cellular response to MMS, most likely
to repair DSBs generated by replication blocks.
Conclusion/Significance: Taken together our results demonstrate that (i) the stabilities of BRCA1/BARD1 complexes are
regulated in a mutagen-specific manner, and (ii) indicate the existence of mechanisms that may be required to prevent the
simultaneous recruitment of conflicting signaling pathways to sites of DNA damage.
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Introduction
Germline mutations in BRCA1 cause extremely high predispo-
sition to breast and ovarian cancers. BRCA1 is a large protein with
a well-established modular structure. It contains two BRCT
domains at the C-terminus, i.e., phospho-peptide binding modules
also carried by several proteins involved in the DNA damage
response. The N-terminus of BRCA1 is characterized by the
presence of a Ring finger domain conferring ubiquitin ligase
activity via stable complex formation with another Ring finger
protein, BRCA1-associated RING domain 1 (BARD1). Although
the precise role(s) of BRCA1/BARD1 in tumor suppression have
not been fully established, ample evidence indicates that this
heterodimer is required to maintain genomic stability following
DNA damage (see reviews [1,2]). During periods of genotoxic
stress BRCA1 is rapidly phosphorylated and thus activated by the
primary responders Ataxia-Telangiectasia-Mutated kinase (ATM)
or ATM- and Rad3-Related kinase (ATR), which in turn
promotes cellular recovery through induction of DNA damage
checkpoints [3,4,5,6,7]. Moreover, recent studies indicate that
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e14027BRCA1/BARD1 selectively associates with several components of
the DNA damage response forming mutually exclusive complexes.
Indeed, through the BRCT domain, BRCA1/BARD1 interacts
with either Abraxas, BACH1, or CtIP, along with other distinct
cofactors, to form multiprotein complexes termed A, B, and C,
respectively. These complexes play important roles in the DNA
damage response by exerting specific although overlapping
functions in cell cycle arrest and DNA repair [2,8].
The role of BRCA1 has been studied mostly in the context of
ionizing radiation (IR), which directly induces highly genotoxic
DNA double-strand breaks (DSBs). Following exposure to IR,
several proteins are rapidly recruited to DSB sites to form IR-
Induced Foci (IRIF). IRIFs are characterized by ATM-mediated
phosphorylation of the histone variant H2AX (cH2AX) [9], which
is required for the subsequent highly coordinated assembly of
checkpoint/repair proteins. The precise mechanism of IRIF
formation is not completely understood, although recent studies
have shed light on the dynamics and orchestration of this process.
The DNA damage mediator MDC1 promotes recruitment of the
E3 ligases RNF8 and RNF168 that ubiquitinate specific substrates
including histones. These events are required for interaction with
the ubiquitin binding protein RAP80, which then recruits
additional factors including BRCA1 and BARD1. At the IRIF,
BRCA1/BARD1 in turn attracts other proteins such as Rad51
and BRCA2 that mediate cell cycle checkpoints and DNA repair
(reviewed recently in [2,8,10]).
In contrast to the situation for IR, the manner in which
BRCA1 responds to genotoxic agents that do not directly induce
DSBs is poorly understood. BRCA1 was initially reported to be
rapidly dispersed from constitutive foci following treatment with
various mutagens [11,12]. These normally-occurring BRCA1
foci (constitutive foci as opposed to IRIF) contain a substantial
pool of BRCA1 and are found in , 40–70% of the cells
[11,13,14]. Little is known about the significance of these foci in
unstressed cells, although one recent study suggests that these
might be associated with replication of pericentric heterochro-
matin [15]. Moreover, the manner in which BRCA1 dispersion
occurs, and thesignificance of thisev en t,r e m ai ntobeel uc i dat ed .
In particular it has been unclear whether there might be a
relationship between this dispersion and changes in protein
stability during DNA damage. Although it is often assumed that
the phosphorylation state, rather than absolute levels, of BRCA1
changes in response to DNA damage [3,5,6,7,16,17,18], some
studies reported that BRCA1 and/or BARD1 are upregulated
following treatment with UV or the topoisomerase II inhibitor
doxorubicin [19,20,21,22,23]. In sharp contrast, other investi-
gations reported that these proteins are downregulated following
treatment with the same agents [24,25]. Recently, it was shown
that BARD1 is downregulated in a proteasome-dependent
manner following treatment with an extremely cytotoxic dose
of UV (70 J/m
2 ) that induces substantial levels of apoptosis [26].
However, under the same conditions, significant changes in
BRCA1 levels were not consistently observed. It is also critical to
emphasize that BRCA1 was shown to be rapidly cleaved during
apoptosis induced by high dose UV, thereby possibly accounting
for the aformentioned inconsistency [27,28,29]. BRCA1 protein
levels and subnuclear localization have also been investigated
following treatment of cells with DNA alkylating agents. One
study reported that this protein accumulates in nuclear foci
following treatment with methylmethanesulfonate (MMS) [30],
whereas another showed that BRCA1 is actually downregulated
by methyl methanethiosulfonate [31]. In summary, it is not yet
clear how BRCA1/BARD1 stability and subcellular localization
areregulatedinresponse todiverse classes of DNAadducts,other
than DSBs, which trigger unique though overlapping signaling
pathways.
Defining how BRCA1 participates in the DNA damage
response is of a major importance not only for understanding
breast and ovarian cancer development, but also towards helping
to improve current cancer therapeutic protocols. For example
several promising clinical trials are based on the use of inhibitors of
the DNA damage-responsive enzyme PARP1 as a means to
selectively target BRCA1-deficient tumor cells [32,33]. In view of
the importance of BRCA1 in cancer development and treatment,
and the conflicting data in the literature as cited above, we were
prompted to carefully evaluate BRCA1 stability and localization in
the cellular response to diverse-acting DNA damaging agents. We
conclusively demonstrate that BRCA1 stability is regulated in a
mutagen-specific manner. Indeed, in the early response to UV and
MMS, but not to IR, dispersion of BRCA1/BARD1 from nuclear
foci is accompanied by ubiquitin-mediated degradation of both
tumor suppressors. Significantly, BRCA1 downregulation does not
involve the major DNA damage-activated PI 3 Kinase Related
Kinases (PIKK) or Mitogen-Activated Protein Kinase (MAPK)
pathways, suggesting that other yet to be identified signaling
mechanisms regulate BRCA1 stability/function following DNA
damage. Furthermore, we reveal that BACH1 and Rad52 are also
degraded in a proteasome-dependent manner indicating that
critical components of the homologous recombination (HR)
machinery are selectively targeted for degradation. Finally, data
is provided suggesting that DNA damage signaling pathways
might need to be coordinated in order to forestall the untimely
recruitment of potentially conflicting DNA damage responses.
Results
BRCA1 is downregulated in response to UVC or MMS, but
not IR
Towards understanding the mechanisms that coordinate
regulation of BRCA1 stability and localization following genotoxic
stress, we initially treated HeLa cells with 30 J/m
2 of 254-nm UV
(UVC) which induces rapid ATR-dependent phosphorylation of
BRCA1 [3,16]. Using an antibody recognizing the N-terminal
region of BRCA1, we found that UVC induced a substantial
decrease in levels of this protein at 3 hrs post-treatment, which
became more marked by 6 hrs (Fig. 1A, top panel). Of note, this
occurred simultaneously with depletion of BRCA1 from nuclear
foci (Fig. 1A. bottom panel). Thus, the previously described
phenomenon of BRCA1 ‘‘dispersion’’ from constitutive foci after
UVC irradiation [11,12] appears to be associated with actual
depletion of the protein. Interestingly, IR treatment which has
been shown to result in early dispersion of BRCA1 from
constitutive foci [11], did not significantly affect BRCA1 protein
levels (Fig. 1B). We also conducted immunoblotting with other
anti-BRCA1 antibodies that map to the middle and C-terminal
regions and found that in each case a substantial fraction of the
protein is downregulated post-UVC (Fig.S1). It is important to
emphasize that BRCA1 is downregulated following treatment with
doses as low as 10 J/m
2 of UVC (Fig.S2). Next, in investigating an
additional diverse-acting genotoxin, we revealed that BRCA1 is
downregulated in a dose-dependent manner following treatment
with the DNA alkylating agent MMS (Fig. 1C and Fig.S3). The
above data demonstrate that the control of BRCA1 stability varies
significantly in a mutagen-specific manner. We also show (Fig. 1D)
that BRCA1 downregulation (i) is not cell-type specific, as it occurs
in various tumor cell lines and moreover (ii) was observed in
primary human fibroblasts, revealing that the downregulation is
not specific to transformed or tumor-derived cells.
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is reversible
To determine whether DNA damage-induced BRCA1 down-
regulation might be a consequence of cell death, HeLa cells were
treated with 200 mM of MMS and harvested at various time points
for immunostaining (Fig. 2A). BRCA1 protein exhibited maximal
decrease at 3–6 hrs followed by its reappearance (reaching nearly
100% of basal levels) by 24 hrs post-treatment indicating that this
decrease is transient. Under the above MMS treatment conditions,
we did not observe cell death as indicated by the absence of any
nuclear condensation typical of apoptosis (see nuclear staining by
DAPI). Consistently, immunoblotting experiments also revealed a
transient downregulation of BRCA1 (Fig. 2B, top panel).
Densitometry quantification of BRCA1 protein levels confirmed
these results (Fig. 2B, low panel). In addition, no cleavage of either
PARP-1 or Caspase-3, two hallmarks of apoptosis, were detected
in MMS-treated cells (Fig. 2B), and moreover no change in cell
viability was observed during the treatments (,100% viability at
all time points as determined by trypan blue exclusion assay). Of
note, to ensure that we were able to actually detect apoptosis in
our experimental system, we treated cells with UVC (100 J/m
2),
and found that this highly toxic dose induced substantial apoptotic
cleavage of Caspase-3 or PARP-1 after only 6 hrs post-treatment
(Fig. 2B, right panel). The above results indicate that downreg-
ulation of BRCA1 is not a consequence of apoptosis, suggesting
that a unique signaling process may underlie the temporal and
spatial regulation of this protein.
BRCA1 downregulation occurs in S and G2 phases of the
cell cycle
Since (i) downregulation of BRCA1 after DNA damage is
partial (Fig. 2), suggesting that this process might be specific to a
distinct cell population, and (ii) BRCA1 is known to be expressed
primarily during S and G2 phases [34], we evaluated whether
DNA damage-induced BRCA1 downregulation might be trig-
gered in a cell cycle-specific manner. HeLa cells were synchro-
nized at the G1/S border using thymidine double block and
treated with MMS for 3 hrs at different times post-release. Cell
cycle profiles with or without MMS exposure reveal that more
than 90% of the cells were in S phase at 5 hrs, and ,80% in G2 at
11 hrs (Fig. 3A top panel). In accord with previous studies [34],
BRCA1 protein levels were dramatically increased in S phase-
enriched populations (Fig. 3A bottom panel, compare 5 hrs versus
Asyn). We found that BRCA1 was downregulated at all time
points examined after MMS treatment. Since the G2 population is
not highly enriched under thymidine block (i.e., contaminated
with S phase cells), we synchronized cells using other methods. G2
cells were highly purified (,95%) after 16 hrs by pre-treatment
with the mitotic inhibitor nocodazole in conjunction with mitotic
shake-off to remove M cells (Fig.S4 left panel). G2 cells treated
with MMS exhibited substantial downregulation of BRCA1 at 3
and 6 hrs (Fig.S4 right panel). We also synchronized primary
human foreskin fibroblasts in G0 through a physiological process,
i.e., contact inhibition, followed by release for various time points
to allow progression through the cell cycle (Fig. 3B). We found that
following UVC treatment, at any time during cell cycle
progression up to 32 hr, BRCA1 is downregulated (Fig. 3B).
The above data taken together conclusively demonstrate that the
primary signal triggering BRCA1 downregulation during periods
of genotoxic stress is not dependent upon cell cycle as might be
expected a priori.
The PI3 kinase related kinases (PIKKs) family members
ATM, ATR and DNA-PK, and the canonical MAPKs, are not
required for signaling BRCA1 downregulation following
DNA damage
ATM, ATR, and DNA-PK initiate multiple signaling cascades
including the phosphorylation-mediated activation, stabilization, or
degradation of various proteins that participate in coordinating the
DNA damage response [35,36]. Since BRCA1 is directly and
rapidly phosphorylated by ATM and/or ATR, we evaluated the
likely possibility of a link between PIKK signaling and BRCA1
downregulation during genotoxic stress. We first treated HeLa cells
with IR or MMS for short time periods and analyzed BRCA1
protein. We found that while IR did not significantly affect BRCA1
protein levels, it induced a substantial shift in protein mobility
strongly suggestive of phosphorylation (Fig. 4A). In contrast, MMS
induced mainly downregulation of the protein with a less significant
effect on protein mobility (Fig. 4A). Thus, phosphorylation is not
correlated with BRCA1 degradation. Next, we used caffeine, a well-
characterized inhibitor of ATM and ATR [37], and found that
while MMS-induced H2AX phosphorylation is strongly inhibited,
BRCA1 downregulation is unaffected (Fig. 4B). Similar conclusions
Figure 1. Downregulation of BRCA1 protein during genotoxic
stress. A) Top, BRCA1 expression in HeLa cells treated with UVC (30 J/
m
2) was detected by immunoblotting after harvesting at the indicated
times. Bottom, immunostaining of BRCA1 at 4 hrs post-treatment. DNA
was counterstained with DAPI. B) BRCA1 levels in HeLa cells treated
with IR (10 Gy) for the indicated times. C) BRCA1 levels in HeLa cells
treated with the DNA alkylating agent, methylmethanesulfonate (MMS,
200 mM) for the indicated times. D) BRCA1 levels in various cell types
treated with 200 mM MMS for the indicated times. All immunoblottings
were conducted using total cell extracts. b-actin was detected to ensure
equal protein loading.
doi:10.1371/journal.pone.0014027.g001
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(Fig. 4C) or ATM-deficient human fibroblasts (Fig. 4D and Fig.S5).
As control for pharmacological inhibition of ATM, abrogation of
Chk2 phosphorylation was evaluated and shown to be reduced
(Fig. 4C). To specifically address the role of ATR, we used an
shRNA construct which induces efficient knockdown of this protein
(Fig. 4E, left panel). Following treatment with MMS, BRCA1 is
downregulated to a similar extent in cells whether depleted or not
for ATR (Fig. 4E, right panel). Finally, paired glioblastoma cell lines
deficient or not in DNA-PK were employed to probe the potential
requirement of the latter in BRCA1 downregulation. BRCA1 levels
were decreased equally in DNA-PK deficient (MO59J) or proficient
Figure 2. BRCA1 downregulation is independent of apoptosis and is reversible. A) Immunostaining of BRCA1 in HeLa cells treated with
200 mM MMS. Cells were harvested at 3 and 6 hrs or changed to MMS free medium for the later times. The nuclei were counterstained with DAPI. B)
Top left, immunoblotting of BRCA1 and apoptosis markers, PARP-1 and Caspase-3, in HeLa cells treated as indicated above. Bottom left, BRCA1 band
intensity was quantified and data are expressed as percentage of untreated cells. Right, immunoblotting for PARP-1 and Caspase-3 following
treatment with high dose of UVC (100 J/m
2).
doi:10.1371/journal.pone.0014027.g002
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dispensable for DNA damage-mediated downregulation of BRCA1
(Fig. 4F and Fig.S5). Finally, we investigated the involvement of the
canonical mitogen-activated protein kinases (MAPKs), including
extracellular signal-related kinase (ERK1/2), c-Jun N-terminal
kinase(JNK1/2),and p38a/b kinase, whicharerapidly activated by
phosphorylation following exposure to genotoxic agents. These
kinases in turn phosphorylate numerous downstream effectors that
influence DNA damage-induced apoptosis, cell cycle checkpoints,
and repair [39,40,41]. We found that inhibition of MAPK signaling
using highly specific pharmacological inhibitors does not affect
BRCA1 downregulation by MMS (Fig.S6). The overall data suggest
that kinases other than PIKKs or MAPK family members, or
possibly signals other than phosphorylation, are involved in
signaling BRCA1 downregulation.
Identification of BRCA1 domains required for DNA-
damage induced BRCA1 downregulation
To provide additional insight into the mechanism of BRCA1
downregulation, we conducted functional mapping studies using
expression constructs encoding BRCA1 variants lacking major
functional domains (Fig. 5A). All the fragments used are expressed
in HeLa cells at levels quite similar or below the levels of
endogenous BRCA1. We observed that BRCA1 deleted for the N-
terminal region (D 1-302 aa) is downregulated to a similar extent
as endogenous BRCA1 following MMS treatment (Fig. 5B). This
demonstrates that the ring finger is dispensable for downregula-
tion, thereby excluding the involvement of BRCA1 ubiquitin ligase
activity, and also indicates that interaction with BARD1 is not
prerequisite for degradation. On the other hand, we found that
BRCA1 deficient in the C-terminal region (D 1527–1863 aa) is
completely resistant to proteasomal degradation, strongly suggest-
ing a requirement for the BRCT domains. We also noted that
BRCA1 missing the aa residues 305-770 is degraded following
MMS treatment. This region contains domains required for
interaction with chromatin remodeling and transcription regula-
tors such as the SWI/SNF complex and ZBRK1 repressor
[42,43], indicating that these latter interacting partners do not play
a role in BRCA1 downregulation following DNA damage.
Interestingly, we found that the middle region (aa 775–1292)
which encompasses the Rad51 interaction domain is essential for
Figure 3. Downregulation of BRCA1 occurs independently of the cell cycle phases. A) Synchronized HeLa cells, using a thymidine double
block (TDB) method, were treated with 200 mM MMS for 3 hrs at various time points post-release. Cell cycle analysis (top panel) and immunoblotting
(low panel) were conducted at the indicated time points. B) Downregulation of BRCA1 during cell cycle progression in primary cells. Top, human
primary fibroblasts were synchronized in G0/G1 by contact inhibition and were released by replating at low density. Bottom, following UVC (30 J/m
2)
treatment for the last 2 hrs, cell were harvested at the indicated times for immunoblotting. b-actin immunodetection was used as loading control.
doi:10.1371/journal.pone.0014027.g003
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or the region spanning aa 775–1292 consistently exhibited
stabilization following MMS exposure, supporting the involvement
of these regions in regulating BRCA1 stability following genotoxic
stress.
DNA damage-dependent downregulation of BRCA1,
BARD1, BACH1 or Rad52 is mediated by the proteasome
To provide insight into the mechanism of BRCA1 downregu-
lation, in cells treated with MMS, we investigated the stability or
activation of major DNA damage response proteins known to be
involved in the BRCA1 pathway (Fig. 6A). We first analyzed
BARD1, the stoichiometric partner of BRCA1, and found that the
former is also downregulated following MMS treatment. In
addition levels of the MRN complex proteins (MRE11, NBS1
and Rad50), BRCC36, RAP80, CtIP and Rad51 all known to
assemble various complexes with BRCA1/BARD1 heterodimer
are not affected by MMS treatment (Fig. 6A). Moreover, no major
changes of RPA protein, a marker for DNA end-resection, were
observed at early time points of BRCA1/BARD1 downregulation.
Strikingly however, this protein was hyperphosphorylated at the
later stage of MMS exposure, as indicated by the typical shift of
protein electrophoretic mobility (Fig. 6A) [45,46,47]. On the other
hand, we did observe downregulation of Abraxas and BACH1,
two other BRCT motif-interacting proteins that define the A and
B complexes respectively (Fig. 6A). Interestingly, while Abraxas
Figure 4. The DNA damage-activated PIKKs family members ATM, ATR and DNA-PK are not required for downregulation of BRCA1.
A) Immunoblotting detection of BRCA1 in HeLa cells treated with 10 Gy IR or 200 mM MMS. B) BRCA1 downregulation is not blocked by caffeine.
Immunoblotting detection of BRCA1 in HeLa cells pre-treated with 10 mM caffeine for 30 min prior to 200 mM MMS treatment for 6 hrs. C) The
downregulation of BRCA1 is not prevented by the ATM inhibitor (KU-55933). Immunoblotting detection of BRCA1 in HeLa cells pre-treated with
10 mM KU-55933 for 30 min prior to 200 mM MMS treatment for 6 hrs. cH2AX and pChk2 detection were used as controls to confirm inhibition of
ATM and/or ATR kinases. D) BRCA1 is downregulated in ATM-deficient human fibroblasts. Cells were treated with 200 mM MMS treatment for 6 hrs
and harvested for immunoblotting. E) Depletion of ATR by RNAi does not prevent BRCA1 downregulation by MMS. Left, immunodetection of ATR
following shRNA constructs transfection and puromycin selection. Right, ATR-depleted cells were treated with 200 mM MMS and harvested at the
indicated times for immunoblotting. F) BRCA1 is downregulated in DNA-PKcs deficient cells. Glioblastoma DNA-PKcs proficient (MO59K) or deficient
(MO59J) were treated with 200 mM MMS and harvested at the indicated times for immunoblotting.
doi:10.1371/journal.pone.0014027.g004
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BACH1 exhibited a biphasic downregulation. Moreover, we
found that levels of the HR protein Rad52, known to act
downstream BRCA1, were significantly reduced. In addition, a
slight shift in Rad52 protein gel mobility was consistently observed
at the later stage of treatment (12 and 24 hours). We also observed
that phosphorylation of the checkpoint kinases Chk1, Chk2, and
the histone variant H2AX appear to be temporally correlated with
reduction in BRCA1/BARD1/BACH1 and Rad52 protein levels
(Fig. 6A). These results indicate that specific components of the
HR machinery are downregulated at the early stage of the cellular
response to MMS exposure and then recovered totally or partially
at later times. Since RPA is hyperphosphorylated at 12 and
24 hours post-treatment, we sought to investigate the subnuclear
localization of critical components of the HR pathway, i.e.,
BRCA1, cH2AX, RPA and Rad51. As expected from immuno-
bloting experiments, cH2AX was strongly induced and moreover
form a substantial number of cH2AX foci that, at the early stage
of treatment (3–6 hours), exhibited no staining for the HR proteins
BRCA1, Rad51 or RPA (Fig. 6B and Fig.S8). Interestingly, at the
later stage (12–24 hours post-treatment), BRCA1, as well as RPA
and Rad51, formed foci indicating DSB processing.
We next evaluated the possibility that MMS-induced downreg-
ulation of BRCA1 and associated partners occurs at the level of
protein stability. First, a cycloheximide chase revealed that
BRCA1 stability is significantly decreased in response to MMS
versus cycloheximide alone, suggesting an active degradation
mechanism (Fig. 7A). In contrast, the abundance of Cdc6, a
protein with short half-life, is substantially decreased by treatment
with cycloheximide, but not with MMS. This result prompted us
to investigate the involvement of active protein degradation in
regulating the stability of BRCA1 and associated partners. We
found that the proteasome inhibitor MG132 completely blocks
downregulation of BRCA1 (Fig. 7B). Similar results were obtained
for BRCA1 following pre-treatment of HCT116 or HeLa cells
with proteasome inhibitors prior to either MMS or UVC exposure
(Fig.S7 A and B). Next, we analyzed additional components and
found that the proteasome is also required for downregulation of
BARD1, BACH1, and Rad52 in HeLa cells treated with MMS
(Fig. 7B). Surprisingly, Abraxas downregulation is not blocked by
MG132 suggesting that a proteasome-independent mechanism
regulates levels of this protein. To demonstrate the involvement of
ubiquitination per se, BRCA1 immunoprecipitated from either
mock- or MMS-treated HEK293T cells was shown to be readily
ubiquitinated following DNA damage (Fig. 7C). A densitometry
quantification indicated that the ubiquitin signal is increased by ,
3-fold following MMS treatment. We confirmed these results in
HeLa, i.e., MMS induced a 3-fold increase in BRCA1 ubiqui-
tination (Fig.S7C). In summary, our results indicate that
proteasomal-mediated degradation of BRCA1/BARD1/BACH1
and of Rad52 is a normal physiological response to DNA
damaging agents that do not directly generate DSBs, and suggest
the existence of a yet-to-be characterized regulatory mechanism
controlling the BRCA1 pathway.
BRCA1/BARD1 downregulation prevents their
recruitment, along with Rad51, to chromatin following
MMS treatment
In response to IR-induced DSBs, phosphorylation of H2AX
engenders a cascade of protein recruitment that culminates in the
assembly of the BRCA1/BARD1/Rad51 HR repair complex at
IRIF. The primary types of DNA damage induced by UVC and
MMS are pyrimidine dimers and alkylated bases, respectively.
These agents also significantly induce cH2AX (Fig. 6 and
discussion). Thus we postulate that early BRCA1/BARD1
downregulation might be needed to prevent their recruitment to
UV- or MMS-damaged chromatin, as this might otherwise
interfere with mutagen specific-signaling events or -repair
processes, i.e., nucleotide excision repair of UV-induced pyrim-
idine dimers or base excision repair of alkylated DNA bases. To
investigate this possibility, we analyzed the recruitment of BRCA1,
BARD1, and Rad51 to chromatin following inhibition of
BRCA1/BARD1 downregulation using the proteasome inhibitor
MG132. As control, we used IR treatment which is known to
rapidly induce the assembly of BRCA1/BARD1/RAD51 on
chromatin (Fig. 8A). We found, in sharp contrast to treatment with
MMS or MG132 alone, that combined treatment with MMS and
MG132 resulted in a highly significant recruitment of BRCA1/
BARD1/RAD51 proteins to chromatin. However, it was
previously shown that proteasome inhibitors block BRCA1 and
Figure 5. The BRCT motif, but not the Ring finger domain, is required for MMS-induced BRCA1 downregulation. A) Schematic view of
the deletion constructs used in this study. B) HeLa cells were transfected with various expression constructs for BRCA1 and 2 days post-transfection,
cells were treated with 200 mM MMS and harvested at the indicated times for immunoblotting to detect either endogenous BRCA1 or mutant forms
using anti-BRCA1 or anti-GFP respectively. b-actin immunodetection was used as a loading control.
doi:10.1371/journal.pone.0014027.g005
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apparent discrepancy. First, we treated HeLa cells with MG132
and found that neither BRCA1 nor Rad51 formed foci following
IR thus reproducing, in our experimental setting, the previously
published findings (Fig.S9). Next, we investigated the subnuclear
localization of these proteins in response to MG132, MMS, or
combined treatments. As control, we used IR to induce BRCA1 or
Rad51 foci formation (Fig. 8B, left panel and Fig.S10). We found
that BRCA1 exhibited strong but diffuse nuclear staining following
treatment with either MG132 or MG132/MMS. As expected, a
very low BRCA1 signal was detected in cells treated with MMS
only. Rad51 staining was diffuse for all treatments except for IR,
which induced its assembly at IRIF. Focus formation was observed
for BRCA1/RAD51/cH2AX following IR, but only for cH2AX
in the case of MMS (Fig. 8B, right panel). Altogether, these results
suggest that BRCA1 and Rad51 might be loaded on chromatin in
response to MG132/MMS without forming distinct foci. To
further demonstrate this, we permeabilized the cells post-treatment
Figure 6. MMS induces a biphasic response of homologous recombination proteins. A) Immunodetection of various BRCA1-associated
and DNA damage/repair proteins following treatment of HeLa cells with 200 mM MMS. HeLa cells were treated with 200 mM MMS and harvested at
the indicated times for immunoblotting. The star indicates the specific protein band detected with a given antibody. B) Foci formation of HR proteins
following MMS treatment. HeLa cells were treated with 200 mM MMS and harvested at the indicated times for immunostaining. Bottom, cells with
more than 10 foci were counted and the data are presented as percentage of cells with foci under each condition. The values represent the average
6 SD of three independent experiments.
doi:10.1371/journal.pone.0014027.g006
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conducted immunostaining as above. As a control for the cell
permeabilization procedure, we analyzed the nuclear protein
BAP1 [50] and observed a substantial decrease of its nuclear
staining (Fig.S11). We found that Rad51 and BRCA1 signals
remained high with MG132/MMS, and to a lesser extent with
MG132 alone, following cell permeabilization (Fig. 8C, left panel
and Fig.S10). In contrast, Rad51 signal was significantly decreased
in the untreated cells and following MMS, most likely due to its
diffusion from the nuclei. Again, focus formation for BRCA1 and
Rad51 was not observed with MG132 or MG132/MMS, as
shown above for intact cells (Fig. 8C, right panel).
We next tested whether exposure to MMS might affect pre-
assembled BRCA1/BARD1/RAD51 at IRIF. Cells were treated
with IR in order to induce IRIF (as revealed by immunostaining
for cH2AX/BRCA1/BARD1/RAD51), followed by treatment
with MMS. This resulted in a dramatic decrease of BRCA1/
BARD1/RAD51 foci, but not of cH2AX foci (Fig. 9A, top and
bottom panels). As expected, immunoblotting indicated that
although BRCA1 and BARD1 are substantially downregulated,
Rad51 protein levels remain unchanged (Fig. 9B).
Discussion
A critical role for BRCA1/BARD1 in the HR branch of DSB
repair following IR exposure is now well established. However
previous studies have reported conflicting results on the regulation
and functionality of this heterodimer in response to genotoxic
agents which induce (i) DNA adducts other than DSBs, and
therefore also (ii) unique signaling pathways relative to the
situation for IR (see Introduction). Here, we resolve these
discrepancies by demonstrating that BRCA1 is actually downreg-
ulated rather than simply relocalized.
Indeed, the previously described dispersion of BRCA1 from
constitutive foci following UVC [11,12], or MMS exposure (this
study), is associated with active degradation of the protein.
However IR, which was shown to induce early dispersion of
BRCA1 from constitutive foci prior to IRIF formation [11], does
not induce BRCA1 downregulation. Thus, distinct signaling
mechanisms are ostensibly responsible for controlling BRCA1
relocalization and/or levels during periods of genotoxic stress
depending upon the nature of the DNA damage. We note that
during our investigation of BRCA1 downregulation following
treatment with UVC or MMS, several critical factors were taken
into consideration that might account for discrepancies between
previous studies and our own: (i) Total cell extracts prepared in 2%
SDS, sonicated, and boiled prior to immunoblotting were used to
exclude the possibility of selective extraction. (ii) Different
antibodies recognizing several regions of BRCA1 were employed,
thus excluding potential artifacts due to epitope masking that
might be caused by post-translational modifications. (iii) Diverse
human strains including primary human fibroblasts were investi-
gated, thus controlling for potential cell-type specific responses. (iv)
We showed that BRCA1 is downregulated following exposure to
relatively low mutagen doses, i.e, 50 mM of MMS or 10 J/m
2 of
UVC, where within the time frame of our analysis cell viability is
Figure 7. The proteasome mediates BRCA1 and BARD1 downregulation following MMS treatment. A) HeLa cells were incubated with
20 mg/ml of cycloheximide alone or with 200 mM MMS (with or without cycloheximide) and harvested at the indicated times for immunoblotting. B)
HeLa cells were pre-treated with 20 mM proteasome inhibitor MG132 for 30 min and then incubated with MMS in the presence of the inhibitor and
harvested at 6 hrs for immunoblotting. C) Detection of BRCA1 ubiquitination following DNA damage in HEK293T cells. Following MMS treatment for
3 hrs, cell extracts were used for immunoprecipitation with an anti-BRCA1 antibody. A non-related polyclonal antibody was used as a control. The
immunoprecipitates were used for immunoblotting using anti-BRCA1 or anti-ubiquitin antibodies. Densitometry quantification was conducted on
BRCA1 and ubiquitin and the ratio ubiquitin/BRCA1 is shown.
doi:10.1371/journal.pone.0014027.g007
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because a previous study had indicated that BRCA1 is cleaved by
Caspase-3 during apoptosis, as early as 3 hrs following treatment
with a very high dose of UV [27]. In addition BRCA1
downregulation is fully reversible, strongly arguing against any
involvement of caspases in this early event. We also emphasize that
10 J/m
2 of UVC is physiologically relevant as this dose induces a
level of DNA photoproducts equivalent to that which can be
obtained during 1 hr of exposure to natural sunlight [51,52].
Regulation of protein stability by the ubiquitin-proteasome
system is a critical determinant of protein function. Several lines
of evidence presented here indicate that BRCA1 is degraded via the
proteasome: (i) UVC or MMS treatment induces dramatic
downregulation of BRCA1 within 2–3 hrs, and this cannot be
Figure 8. BRCA1/BARD1 downregulation prevents recruitment of these proteins along with Rad51 to chromatin following MMS
treatment. A) HeLa cells were treated for 6 hrs with IR (10 Gy) or 200 mM MMS (with or without pretreatment with MG132). Chromatin from control
or treated cells was prepared as described in material and methods and proteins were detected by western blotting. Histones were stained with
coomassie blue to ensure equal loading. B) HeLa cells were treated as in panel A and harvested for immunostaining (left panel). Cells with more than
10 foci were counted and the data are presented as percentage of cells with foci under each condition (right panel). The values represent the average
6 SD of three independent experiments. C) HeLa cells were treated as in A except that a permeabilization step was added before fixation and
immunostaining (left panel). Cells with more than 10 foci were counted and the data are presented as percentage of cells with foci under each
condition (right panel). The values represent the average 6 SD of three independent experiments.
doi:10.1371/journal.pone.0014027.g008
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transcription/translation arrest since complete inhibition of protein
synthesis by cycloheximide revealed that the half-life of BRCA1 is
,4 h ([34] and this study). In addition, downregulation of BRCA1
in response to MMS treatment cannot be enhanced by pretreat-
ment with cycloheximide, indicating that an active degradation
process predominates with respect to constitutive turnover of
BRCA1. (ii) Importantly, two different proteasome inhibitors
(ZL3VS [53] and MG132 [54]) were used to minimize the
possibility of non-specific effects. (iii) We established that BRCA1
is ubiquitinated following MMS treatment. It should be emphasized
that a ubiquitination signal is also observed below that of full length
BRCA1, as degradation occurs during the process of immunopre-
cipitation (Fig. 7C and Fig.S7C). Moreover other interacting
partners of BRCA1, including BARD1 and BACH1, would also
be expected to contribute to the ubiquitination signal, since these
proteins are co-regulated in a proteasome-dependent manner.
Building on the firm conclusions above, we decided to further
elucidate novel aspects pertaining to the mechanism and signifi-
cance of BRCA1/BARD1 degradation following genotoxic stress.
Figure 9. The DNA alkylating agent MMS induces the disassembly of BRCA1/BARD1/Rad51 from IRIF. A) U2OS cells were pre-treated
with IR (10 Gy) for 12 hrs and then with or without 200 mM MMS for 6 hrs and harvested for immunostaining. Bottom, cells with more than 10 foci
were counted and the data are presented as percentage of cells with foci under each condition. The values represent the average 6 SD of three
independent experiments. B) Immunoblotting detection of BRCA1, BARD1 and Rad51 in HeLa cells pre-treated with IR (10 Gy) for 12 hrs and then left
untreated or exposed to 200 mM MMS for 3 and 6 hrs.
doi:10.1371/journal.pone.0014027.g009
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the current study is the rapid phosphorylation of BRCA1 by PIKK
family members following genotoxic insult. Indeed the notion that
PIKK signaling is required for transient proteasome-mediated
downregulation of critical DNA damage responsive proteins is not
without precedent. For example it was previously observed that
the cyclin-dependent kinase inhibitor p21waf1 is downregulated
by UVC and MMS, but not by IR, and this depends upon
functional ATR kinase [55,56]. Also the very rapid phosphory-
lation of BRCA1 by ATR following UV is temporally associated
with BRCA1 degradation observed here. Despite these consider-
ations, we found that inhibition of ATR, ATM, or DNA-PK does
not block or enhance BRCA1 downregulation, supporting the
notion that PIKK-mediated BRCA1 phosphorylation, and
degradation of the protein, represent distinct signaling processes
acting to control BRCA1 function. It is noteworthy that in
addition to ATM, ATR, DNA-PK and MAPK, we also
investigated, using specific chemical inhibitors, the potential
involvement of several other kinases implicated in the DNA
damage response including casein kinase 2 and cyclin-dependent
kinase 2 each known to phosphorylate BRCA1 [57,58]. Using
various inhibitor concentrations, we failed to observe any
interference with BRCA1 downregulation by MMS (data not
shown). Taken together our data strongly suggest that phosphor-
ylation might not be involved in triggering BRCA1 degradation.
Thus, the possible involvement of other post-translational
modifications or signaling events in triggering BRCA1 degradation
appears quite plausible. In this respect, our work sets the stage for
further studies focused on unraveling the novel signaling
mechanism mediating BRCA1 downregulation following UVC-
or MMS-induced DNA damage.
Interestingly we found that BRCA1 variants lacking BRCT
motifs or the region spanning aa 775–1292 were not only
completely resistant to degradation, but also consistently exhibited
stabilization following MMS treatment. This suggests that (i) the
aforementioned domains contain protein interaction motifs or sites
for post-translational modifications (including ubiquitination sites)
that induce degradation, and (ii) along with the engagement of
active degradation, a feedback process of BRCA1 stabilization
might be concomitantly induced by MMS, and this later event
becomes effective only when the signaling responsible for
degradation is terminated or inhibited. This feedback loop would
contribute to the re-establishment of BRCA1 protein levels at the
appropriate time post-genotoxic stress. Further investigations are
required to address the molecular mechanism underlying this
dynamic regulation of BRCA1 stability.
It appears counterintuitive that the function of a tumor
suppressor is abrogated during periods of genotoxic stress. We
postulate that the biological significance of BRCA1 downregula-
tion likely reflects a necessity to temporally coordinate DNA
damage signaling and repair pathways in response to specific
classes of DNA adducts. Such coordination has been proposed for
other tumor suppressors involved in the maintenance of genomic
integrity including the checkpoint kinase Chk1 and the DNA
damage binding protein DDB2 [59,60,61]. Of particular note, the
early transient proteasome-dependent degradation of p21waf1
mentioned above was shown to be required for efficient repair of
DNA damage after UV irradiation [55,56]. IR is well known to
directly generate DSBs leading to rapid ATM/DNA-PK activa-
tion followed by phosphorylation of H2AX and subsequent DSB
repair via non-homologous end-joining or HR. On the other hand
neither UVC nor MMS generates DSBs as primary lesions,
although both induce replication stress resulting in a delayed
formation of DSBs at collapsed replication forks, which in turn
induces ATM-dependent phosphorylation of H2AX [62,63,64].
Interestingly, it has also been reported that alkylation base damage
can induce cH2AX in the complete absence of replication
blockage [65]. In addition, it was clearly shown that cH2AX is
upregulated by UVC treatment in the absence of DSBs and
moreover associates with sites of nucleotide excision repair [66].
The exact significance of H2AX phosphorylation under such
conditions is not yet clear. However since this histone modification
might promote the recruitment of DSB repair proteins per se,i t
appears reasonable that critical compensatory mechanisms would
be engaged to prevent the initiation of conflicting DNA damage/
repair responses, i.e., in instances where no DSBs are actually
induced. In fact we provide evidence that BRCA1/BARD1
degradation might prevent the untimely association of HR repair
proteins with MMS-damaged chromatin, which would otherwise
interfere with specific signaling events induced by alkylated DNA
bases or with the execution of base excision repair. In support of
this, following MMS treatment, we observed downregulation of
the HR proteins Rad52, BACH1 and Abraxas, which are not
immediately required to process DNA alkylation damage. For
example, Rad52 interacts with Rad51, associates with single-
stranded DNA ends, and promotes the annealing of complemen-
tary DNA strands [67]. Thus, its association with DNA repair
intermediates generated during the processing of alkylated bases
might well compromise the efficiency of base excision repair. We
emphasize that downregulation of components of the HR
machinery during the initial period of MMS treatment is followed
by a second phase of recovery. We note that unlike BRCA1 and
BARD1, Rad52 downregulation by MMS is not followed by
complete recovery at 24 hours. This might suggest that only a
small portion of Rad52 is needed at the later stage of MMS
response, time at which HR pathway is activated. Consistent with
this, a shift in Rad52 protein mobility was observed at 12 and
24 hours likely reflecting phosphorylation that might modulate its
function in HR. Indeed, we observed at later stages of MMS that
typical HR foci are formed and are highly enriched in BRCA1,
RPA and Rad51. Importantly, foci formation was also concom-
itant with RPA hyperphosphorylation, a marker for DSBs
processing. Clearly, the process of repair takes place after the
initial phase of BRCA1/BARD1 downregulation, most likely to
repair DSBs generated by replication blocking lesions. We propose
a model integrating our findings, which highlight the biphasic
response of HR machinery to MMS (Fig. 10).
In conclusion we have demonstrated that BRCA1/BARD1 stability
and hence function is tightly regulated by ubiquitination-mediated
proteasomal degradation in response to UV or MMS exposure, in a
manner entirely distinct to that observed following treatment with IR.
It would be extremely interesting to identify the ubiquitin ligase
mediating BRCA1/BARD1 downregulation, as well as to determine
how defects in this pathway affect tumor suppressor function.
Materials and Methods
Chemicals and plasmids
The pharmacological kinase inhibitors U0126, SP600125, and
SB202190 were from Cell Signaling. Nocodazole, caffeine, cyclo-
heximide and MG132 were from Sigma-Aldrich and KU-55933
from Calbiochem. GFP-tagged full-length BRCA1 and BRCA1
deletion mutants were provided by Dr. N. Chiba [68]. ZL3VS
proteasome inhibitor was a generous gift of Dr. B.M. Kessler [53].
Cell culture and DNA damage treatments
HeLa cervical cancer, U2OS osteosarcoma, HEK293 embry-
onic kidney, HCT116 colon carcinoma and low passage primary
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ATM-deficient primary skin fibroblasts (HDSF, AG04405A) from
the Coriell Institute. The MO59K (DNA-PK proficient) and
MO59J (DNA-PK null) glioblastoma cell lines were provided by
Dr. M.J. Allalunis-Turner [69]. All strains were cultured in
DMEM supplemented with 10% foetal bovine serum, L-glutamine
and antibiotics. Cell monolayers were washed with phosphate-
buffered saline (PBS), covered with PBS, and irradiated with UVC
using a crosslinker (CL-1000, VWR) at a fluency of 5 J/m
2/s and
returned to culture medium. IR exposure was performed using a
cesium-137 source (Gamma Cell; Atomic Energy Canada) at a
dose rate of 6.3 rad/s. Methylmethanesulfonate (MMS) (Sigma-
Aldrich) was added to the culture medium at the indicated
concentrations.
Synchronization and cell cycle analysis
Primary fibroblasts we synchronized in G0/G1 by contact
inhibition [34]. HeLa and U2OS cells were synchronized at the
G1/S border using a thymidine double block protocol [70]. G2/
M populations were obtained following 16 hours (hrs) of treatment
with nocodazole (200 ng/ml) used to prevent cells from cycling.
G2 cells were separated from M cells by mitotic shake off. Cell
cycle analysis was carried out as described [71] using a FACScan
flow cytometer fitted with CellQuestPro software (BD Biosciences).
shRNA knockdowns
shRNA targeting ATR (TRC0000039615) was purchased from
Sigma-Aldrich. The non-target control shRNA was described
[72]. Cells were transfected with either shRNA and selected in
medium containing puromycin for 2 days as described [71].
Immunostaining and immunoblotting
All antibodies are described in Table S1. Western blotting using
total cell extracts was performed as described [71]. The band
signals were directly acquired with a LAS-3000 LCD camera
coupled to MultiGauge software (Fuji, Stamford, CT, USA).
Immunostaining was performed as described [71] except that the
secondary antibodies Alexa Fluor 488 goat anti-mouse IgG or an
Alexa Fluor 594 goat anti-rabbit IgG (Invitrogen) were used.
Nuclei were counterstained with DAPI. Nuclei permeabilization
was essentially conducted as previously described [49]. Fluores-
cence was visualized with a Leica DMRE microscope, and the
data acquired using a RETIGA EX digital camera (QIMAGING)
coupled with OpenLab 3.1.1 software (OpenLab).
Immunoprecipitation
Cell extracts from control or MMS-treated cells were prepared
as described [71] except that 20 mM of N-EthylMaleimide (NEM)
was added to the lysis buffer. After sonication and centrifugation,
lysates were incubated with anti-BRCA1 or a control IgG for 5 to
6 hrs. Immunocomplexes were recovered following 2 hrs incuba-
tion with protein G-sepharose, extensively washed with the
lysis buffer, and eluted with Laemmli sample buffer for
immunoblotting.
Isolation of chromatin
Following DNA damage treatments, cells were washed with
PBS and then resuspended in high-detergent containing buffer
(50 mM Tris-HCl, pH 7.3; 5 mM EDTA; 150 mM KCl; 10 mM
NaF, 1% Triton X-100; 1 mM phenylmethylsulfonyl fluoride
(PMSF); and protease inhibitors cocktail (Sigma). Following 3
successive extractions for 15 minutes each with the same buffer,
the chromatin fraction was recovered by centrifugation at 6000 g/
10 min. Chromatin and total cell extracts were then used for
determination of protein concentration and western blotting.
Supporting Information
Figure S1 Immunoblotting detection of BRCA1 at various times
post-UV using additional specific antibodies. (A–B) HeLa cells
were treated with UVC (30 J/m
2) and harvested at the indicated
times for immunodetection with anti-BRCA1 antibodies. The
monoclonal SD118 antibody which recognizes the C-terminus (A),
or the polyclonal rabbit specific for the middle region (Sankaran et
al., 2006) (B), were used. Immunodetection of b-actin was used as
loading control.
Found at: doi:10.1371/journal.pone.0014027.s001 (0.59 MB TIF)
Figure S2 Downregulation of BRCA1 with low dose of UVC.
Immunoblotting detection of BRCA1 in HeLa cells following
treatment with UVC (10 J/m
2). Immunodetection of PARP-1 was
used as loading control.
Found at: doi:10.1371/journal.pone.0014027.s002 (0.52 MB TIF)
Figure S3 Dose-dependent downregulation of BRCA1 following
MMS treatment. HEK293 Cells were harvested at the indicated
time points for immunoblotting with anti-BRCA1 and anti-b-actin
antibodies (left panel). The band signals were directly acquired
with a LAS-3000 LCD camera (Fuji, Stamford, CT, USA) coupled
to MultiGauge software (Fuji). The protein levels are relative
values and are expressed as a ratio BRCA1/b-actin (right panel).
Found at: doi:10.1371/journal.pone.0014027.s003 (0.65 MB
TIF)
Figure 10. Model indicating a biphasic response of the
homologous recombination pathway induced by the alkylat-
ing agent MMS. In response to MMS, human cells induce a signaling
pathway that culminates in BRCA1/BARD1 downregulation. This
prevents the unwanted assembly of the HR machinery at the early
stage of the MMS-induced DNA damage response. At the second stage,
recovery and assembly of HR proteins ensure the repair of DSBs
generated by replication blocks.
doi:10.1371/journal.pone.0014027.g010
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PLoS ONE | www.plosone.org 13 November 2010 | Volume 5 | Issue 11 | e14027Figure S4 Downregulation of BRCA1 occurs in G2 phase.
HeLa cells were synchronized in G2/M after 16 hrs exposure to
nocodazole. Mitotic cells were removed by shake off and the
purified G2 population was treated with 200 mM MMS for 3 hrs
at various time points post-removal of nocodazole. Cell cycle
analysis (left panel) and immunoblotting (right panel) were
conducted at the indicated time points.
Found at: doi:10.1371/journal.pone.0014027.s004 (0.63 MB TIF)
Figure S5 Immunodetection of ATM or DNA-PK in the cell
lines used. Left, HeLa or ATM-deficient fibroblasts were used for
immunodetection with anti-ATM antibody. Right, Immunostain-
ing detection of DNA-PKcs in glioblastoma cell lines, proficient
(MO59K) or deficient (MO59J).
Found at: doi:10.1371/journal.pone.0014027.s005 (0.68 MB TIF)
Figure S6 DNA damage-activated MAPKs are not required for
downregulation of BRCA1. Cells were pre-treated with 20 mM
U0126, 30 mM SP600125, or 20 mM SB202190 for 30 min to
inhibit signaling pathways involving ERK1/2, JNK1/2, or p38a/
b, respectively (Rouget et al. 2008). Cells were then treated with
200 mM MMS and harvested after 3 hrs. Abrogation of MAPK
signaling following MMS treatment was evaluated by quantifica-
tion of MAPK phosphorylation using anti-phospho-ERK1/2,
-JNK1/2 antibodies. The inhibition of p38a/b activity was
assessed by levels of phosphorylated form of its substrate
MAPKAPK2 (MK2), which can be readily distinguished from
the unphosphorylated form by band shift using anti-MK2
antibody. b-actin immunodetection was used as a loading control.
Found at: doi:10.1371/journal.pone.0014027.s006 (0.90 MB TIF)
Figure S7 The proteasome mediates BRCA1 downregulation in
response to DNA damage. (A) HCT116 cells were pre-treated with
20 mM of the proteasome inhibitor MG132 for 30 min and then
treated with 200 mM MMS in the presence of the inhibitor, and
then harvested at the indicated times for immunoblotting. (B)
HeLa cells were pre-treated with 20 mM of another proteasome
inhibitor ZL3VS for 30 min and then treated with 30 J/m
2 UVC
in the presence of the inhibitor and harvested at the indicated
times for immunoblotting. PARP-1 was used as a loading control.
(C) Detection of BRCA1 ubiquitination following DNA damage in
HeLa cells. Following MMS treatment for 3 hrs, cell extracts were
used for immunoprecipitation with an anti-BRCA1 antibody. A
non-related polyclonal antibody was used as a control. The
immunoprecipitates were used for immunoblotting using anti-
BRCA1 or anti-ubiquitin antibodies. Densitometric quantification
was conducted on BRCA1 and ubiquitin and the ratio ubiquitin/
BRCA1 is shown.
Found at: doi:10.1371/journal.pone.0014027.s007 (1.11 MB TIF)
Figure S8 Immunostaining for BRCA1, Rad51, RPA or
cH2AX following MMS treatment. HeLa cells were treated with
200 mM MMS and harvested for immunostaining.
Found at: doi:10.1371/journal.pone.0014027.s008 (1.44 MB TIF)
Figure S9 Immunostaining for BRCA1, Rad51 and cH2AX
following IR and proteasome inhibition. HeLa cells were treated
for 6 hrs with IR (10 Gy) (with or without pretreatment with
MG132) and harvested for immunostaining.
Found at: doi:10.1371/journal.pone.0014027.s009 (1.44 MB TIF)
Figure S10 Immunostaining for BRCA1, Rad51 and cH2AX in
various conditions. HeLa cells were treated for 6 hrs with IR
(10 Gy) or 200 mM MMS (with or without pretreatment with
MG132) and harvested for immunostaining with (top panel) or
without (bottom panel) a permeabilization step.
Found at: doi:10.1371/journal.pone.0014027.s010 (2.22 MB TIF)
Figure S11 Immunostaining for BAP1 following permeabiliza-
tion. HeLa cells were harvested for immunostaining with (botton
panel) or without (top panel) a permeabilization step.
Found at: doi:10.1371/journal.pone.0014027.s011 (0.74 MB TIF)
Table S1 Antibodies used in this study.
Found at: doi:10.1371/journal.pone.0014027.s012 (1.23 MB
TIF)
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